Signadori is advancing a platform designed to overcome the challenges of treating solid cancers
Category: News
The candidate is being evaluated as both a monotherapy and in combination pembrolizumab
Approximately 59,000 LG-IR-NMIBC patients experience recurrent disease every year in the US
Collaboration aims to improve rapid detection and personalised treatments
Results suggest bispecific antibody combination could improve outcomes
Biotech firm shares phase 2 findings on novel osteoarthritis treatmen
EMHA calls for its inclusion in EU neurological health strategy
Three-year data highlights inflammation control in psoriatic arthritis
Rheumatology studies show promising results for Sjogren’s disease
Biotech firm to collaborate with NHS on early detection study